Rongcheng Luo
Overview
Explore the profile of Rongcheng Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
4941
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang J, Zhang B, Peng L, Liu X, Sun J, Su C, et al.
Ther Adv Med Oncol
. 2023 Jul;
15:17588359231187205.
PMID: 37484525
Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have...
2.
Zhang X, Wu J, Qiao L, Chen L, Chen C, Zhang H, et al.
Front Oncol
. 2023 Feb;
13:1008828.
PMID: 36776338
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed/refractory (R/R) hematological malignancies, especially in R/R B-cell acute lymphocytic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), and multiple...
3.
Tu W, Xiao Y, Wang Y, Luo R, Chen Z
Drugs Today (Barc)
. 2022 Mar;
58(3):117-132.
PMID: 35274631
The introduction of new classes of drugs for the treatment of multiple myeloma (MM) in the past 2 decades, such as proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies, coupled with...
4.
Xiong A, Li L, Li W, Yu J, Lian Z, Zhang Z, et al.
Am J Transl Res
. 2021 May;
13(4):2617-2625.
PMID: 34017421
WW45 is a recently-discovered tumor suppressor gene. Overexpression of WW45 was found to significantly weaken proliferation and colony formation in a human breast cancer cell line, but the molecular mechanism...
5.
Zhao M, Luo R, Liu Y, Gao L, Fu Z, Fu Q, et al.
Nat Commun
. 2021 May;
12(1):2997.
PMID: 33990567
No abstract available.
6.
Cheng C, Li W, Peng X, Liu X, Zhang Z, Liu Z, et al.
Mol Ther Methods Clin Dev
. 2021 Mar;
20:615-624.
PMID: 33718512
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in Chinese and other Southeast Asians. We aimed to explore the precise mechanism for NESG1 in NPC for understanding...
7.
Xu Y, Cai H, Tu W, Ding L, Luo R
Appl Immunohistochem Mol Morphol
. 2021 Feb;
29(7):513-518.
PMID: 33605574
PA2G4 plays a dual role in tumors. However, the correlation of its expression with clinical feature and prognosis has never been reported in nasopharyngeal carcinoma (NPC). Using immunohistochemical staining, we...
8.
Xue Y, Lai X, Li R, Ge C, Zeng B, Li Z, et al.
Front Oncol
. 2021 Feb;
10:607362.
PMID: 33604290
Background: In clinical applications of CAR T-cell therapy, life-threatening adverse events including cytokine release syndrome and neurotoxicity can lead to treatment failure. Outcomes of patients treated with anti-CD30 CAR T-...
9.
Liu J, Wen Y, Liu Z, Liu S, Xu P, Xu Y, et al.
Mol Ther Nucleic Acids
. 2021 Jan;
23:324-335.
PMID: 33425490
VPS33B is reported to be a tumor suppressor in hepatocellular carcinoma, nasopharyngeal carcinoma, colon cancer, and lung adenocarcinoma. Here, we observed that reduced VPS33B protein level was an unfavorable factor...
10.
Liang H, Lin Z, Ye Y, Luo R, Zeng L
Acta Biochim Biophys Sin (Shanghai)
. 2020 Dec;
53(1):85-93.
PMID: 33367479
Colorectal cancer (CRC) is one of the most lethal cancers worldwide. The expression of β-arrestin2 (β-Arr2, ARRB2) in CRC has been well investigated; however, its exact mechanism causing the cancer...